Literature DB >> 16476268

[Melanoma epidemiology in Spain].

Soledad Sáenz1, Julián Conejo-Mir, Aurelio Cayuela.   

Abstract

Spain has one of Europe's lowest melanoma incidence and mortality rates. Nevertheless, it is one of the fastest-growing pathologies in our country, with a 181.3% increase in the incidence rate in men and 205.3% increase in women. It represents 1.3% and 2.5% of malignant tumors in men and women, respectively, while the current standardized worldwide rate is respectively 2.4% and 4.9%. The highest incidence levels correspond to Tarragona for men (6.81%) and Gerona for women (8.24%), and lowest to the Canary Islands and Zaragoza (3.55% and 4.27% for women and men, respectively). This higher incidence among females differentiates Spain from the rest of Europe, where the opposite occurs. Mortality has also increased in Spain in the last few decades (1.76% in males and 1.26% in females), although this rising trend has stabilized in recent years. Spain's mortality rate is the lowest in Europe, as the EUROCARE-III study revealed. This study found an increase of 70.4% in the survival rate for men and 84.1% for women in the 1980s, while the figures for the 1990s were 73.9% for men and 89.8% for women. This low mortality rate in Spain may be due to the increase in thin melanomas, due to early diagnosis and surgical treatment.

Entities:  

Mesh:

Year:  2005        PMID: 16476268     DOI: 10.1016/s0001-7310(05)73105-7

Source DB:  PubMed          Journal:  Actas Dermosifiliogr        ISSN: 0001-7310


  5 in total

1.  The incidence of skin melanoma in Gran Canaria (Canary Islands, Spain) is lower than expected in Southern Europe despite high-risk environmental conditions: an island-wide cross-sectional study.

Authors:  Mercè Grau-Pérez; Gregorio Carretero; Pablo Almeida; Elena Castro-González; María Del Pilar de-la-Rosa-Del-Rey; Jesús María González-Martín; Leopoldo Borrego
Journal:  Cancer Causes Control       Date:  2021-03-01       Impact factor: 2.506

2.  A retrospective chart review study describing metastatic melanoma patients profile and treatment patterns in Spain.

Authors:  I Márquez-Rodas; A Arance; A Berrocal; C L Larios; J Curto-García; I X Campos-Tapias; A B Blanca; S Martin-Algarra
Journal:  Clin Transl Oncol       Date:  2019-08-21       Impact factor: 3.405

3.  Comparative safety of BRAF and MEK inhibitors (vemurafenib, dabrafenib and trametinib) in first-line therapy for BRAF-mutated metastatic melanoma.

Authors:  Ana Cebollero; Teresa Puértolas; Isabel Pajares; Lourdes Calera; Antonio Antón
Journal:  Mol Clin Oncol       Date:  2016-08-04

4.  A meta-analysis of XPD/ERCC2 Lys751Gln polymorphism and melanoma susceptibility.

Authors:  Yalin Sun; Hao Zhang; Haifeng Ying; Wencheng Jiang; Qiwen Chen
Journal:  Int J Clin Exp Med       Date:  2015-08-15

5.  A customized pigmentation SNP array identifies a novel SNP associated with melanoma predisposition in the SLC45A2 gene.

Authors:  Maider Ibarrola-Villava; Lara P Fernandez; Santos Alonso; M Dolores Boyano; Maria Peña-Chilet; Guillermo Pita; Jose A Aviles; Matias Mayor; Cristina Gomez-Fernandez; Beatriz Casado; Manuel Martin-Gonzalez; Neskuts Izagirre; Concepcion De la Rua; Aintzane Asumendi; Gorka Perez-Yarza; Yoana Arroyo-Berdugo; Enrique Boldo; Rafael Lozoya; Arantxa Torrijos-Aguilar; Ana Pitarch; Gerard Pitarch; Jose M Sanchez-Motilla; Francisca Valcuende-Cavero; Gloria Tomas-Cabedo; Gemma Perez-Pastor; Jose L Diaz-Perez; Jesus Gardeazabal; Iñigo Martinez de Lizarduy; Ana Sanchez-Diez; Carlos Valdes; Angel Pizarro; Mariano Casado; Gregorio Carretero; Rafael Botella-Estrada; Eduardo Nagore; Pablo Lazaro; Ana Lluch; Javier Benitez; Conrado Martinez-Cadenas; Gloria Ribas
Journal:  PLoS One       Date:  2011-04-29       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.